WHY CHOOSE personalizedx FOR ALK?
When an oncologist is considering the application of a targeted therapeutic drug for a patient, it’s important to have reliable diagnostic test results. For NSCLC patients for whom the targeted drug XALKORI® may be appropriate, there is an FDA-approved companion diagnostic, commercially known as Vysis ALK (Vysis ALK Break Apart FISH Probe), a FISH-based (fluorescence in situ hybridization) test.
Vysis ALK has these primary benefits:
- The test accurately identifies ALK gene rearrangements in NSCLC patients.
- Early FISH testing at diagnosis can assist physicians in determining appropriate ALK-directed therapy.
- Vysis ALK is the only FDA-approved ALK companion diagnostic validated in XALKORI® (crizotinib) clinical trials.
The National Comprehensive Cancer Network (NCCN GUIDELINES™) recognizes the Vysis ALK Break Apart FISH Probe Kit (Vysis ALK) as a specifically designed method for identifying ALK-rearranged adenocarcinomas.1 Vysis ALK provides reliable information to oncologists that can aid in the appropriate application of ALK-directed therapy.
Vysis ALK is intended for all NSCLC tissue specimens, including not otherwise specified (NOS) specimens.
1. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Non-Small Cell Lung Cancer (Version 2.2013). ©2013 National Comprehensive Cancer Network, Inc. Available at http://www.nccn.org.